Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Kura Oncology (NASDAQ:KURA) on Thursday, setting a price target of $40, which is approximately 52.96% above the present share price of $26.15.
R. Cann expects Kura Oncology to post earnings per share (EPS) of -$0.45 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Kura Oncology, with an average price target of $44.
The analysts price targets range from a high of $60 to a low of $30.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$26.33 million. The company's market cap is $1.73 billion.
According to TipRanks.com, Brookline Capital Markets analyst Leah R. Cann is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5% and a 48.46% success rate.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.